Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genzyme Molecular Oncol. (NasdaqNM:GZMO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
One Kendall Square
Cambridge, MA 02139
Phone: (617) 252-7500
Fax: (617) 494-6561
Employees (last reported count): 4,400
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 3%
·Institutional: 28% (29% of float)
(95 institutions)
·Net Inst. Buying: 582.0K shares (+10.95%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genzyme Molecular Oncology, a division of Genzyme Corporation, is developing a new generation of cancer therapeutics based upon the growing understanding of the molecular basis of cancer. These therapeutics are expected to potentially treat multiple types of cancer, minimize toxicity and side effects, and complement both existing and novel therapies. Genzyme Molecular Oncology supplements its internal resources through collaborations with scientists and clinicians in the field of cancer. Genzyme Molecular Oncology is developing products primarily focused on vaccines that treat cancer by stimulating the body's immune system to fight tumor cells and angiogenesis inhibitors that treat cancer by preventing the formation and development of blood vessels that tumors require for growth.
More from Market Guide: Expanded Business Description

Financial Summary
Genzyme Molecular Oncology is engaged in the development and commercialization of novel cancer products focusing on cancer vaccines and angiogenesis and inhibitors. For the six months ended 6/30/01, revenues decreased 24% to $2.7 million. Net loss increased 18% to $14.6 million. Revenues reflect the absence of a product development milestone payment from Schering-Plough Ltd. Net loss was partially offset by the absence of a $5.4 million amortization of intangibles expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Henri Termeer, 55
Chairman, Pres and CEO
$1.9M
Michael Wyzga, 46
CFO, Chief Accounting Officer, Sr. VP-Fin.
--  
Earl Collier, Jr., 53
Exec. VP; Pres, Genzyme Biosurgery
814K
G. Jan Van Heek, 51
Exec. VP of Therapeutics and Genetics
649K
Peter Wirth, 50
CLO, Exec. VP of Corp. Devel. and Clerk
772K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GZMOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$6.625
Recent Price$9.90 
52-Week High
on 3-Nov-2000
$17.125
Beta-0.40 
Daily Volume (3-month avg)69.0K
Daily Volume (10-day avg)44.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-29.0%
52-Week Change
relative to S&P500
-4.7%
Share-Related Items
Market Capitalization$165.1M
Shares Outstanding16.7M
Float16.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.32 
Earnings (ttm)-$1.61 
Earnings (mrq)-$0.52 
Sales (ttm)$0.31 
Cash (mrq)$0.97 
Valuation Ratios
Price/Book (mrq)31.07 
Price/EarningsN/A 
Price/Sales (ttm)32.04 
Income Statements
Sales (ttm)$4.84M
EBITDA (ttm)-$26.7M
Income available to common (ttm)-$25.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-120.54%
Return on Equity (ttm)-213.31%
Financial Strength
Current Ratio (mrq)1.75 
Debt/Equity (mrq)0 
Total Cash (mrq)$16.2M
Short Interest
As of 8-Aug-2001
Shares Short417.0K
Percent of Float2.6%
Shares Short
(Prior Month)
578.0K
Short Ratio10.69 
Daily Volume39.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.